News & Updates

Show Multimedia Only
Ritlecitinib, brepocitinib superior to placebo for inducing remission in UC

Ritlecitinib, brepocitinib superior to placebo for inducing remission in UC

13 Jan 2023

Ritlecitinib and brepocitinib as induction therapies for ulcerative colitis (UC) appear to be more effective than placebo while having an acceptable short-term safety profile, according to the results of a phase IIb study.

13 Jan 2023